What can we learn from mummy DNA? Is Pfizer single-handedly propping up biotech? And how do you get molecules to “click”?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The newest Nobel laureates got their phone calls from Stockholm this week, and STAT science writer Megan Molteni joins us to explain their prize-winning work in medicine and chemistry. We also discuss the latest news in the life sciences, including the state of biotech dealmaking and the evolution of Amylyx Pharmaceuticals.
With mRNA’s exciting therapeutic potential, biopharma prepares to drive vital progress
The convergence of mRNA and other advances like CRISPR, immuno-oncology, and intracellular antibodies has created a perfect storm that can change the course of medicine. Now, with the scientific community closer than ever to realizing the power of many exciting areas of research, companies are preparing to support extraordinary progress in therapeutic development and clinical care. Scott Ripley, general manager of nucleic acid therapeutics at Cytiva, tells us more.
No comments